News
New study identifies targets for immunotherapy in two breast cancer subtypes
Published on January 10, 2024
Breast cancer is the most common cancer in the world. There are several subtypes that differ immunologically, some generating stronger immune responses than others. The team led by Claude Perreault, Director of IRIC’s Immunobiology Research Unit, used a proteogenomic approach to study the immunopeptidome of two breast cancer subtypes: hormone receptor-positive breast cancer and triple-negative breast cancer. They identified several new antigens for each subtype, which were also shown to generate an immune response in vitro. These new antigens therefore represent potential targets for cancer immunotherapy. The project was led by doctoral student Eralda Kina and is published in The Journal of Clinical Investigation.
Watch the visual abstract by Eralda Kina and Claude Perreault :
Cited study :
Kina E, Laverdure J-P, Durette C, Lanoix J, Courcelles M, Zhao Q, Apavaloaei A, Larouche J-D, Hardy M-P, Vincent K, Gendron P, Hesnard L, Thériault C, Ruiz Cuevas MV, Ehx G, Thibault P, and Perreault C. Breast cancer immunopeptidomes contain numerous shared tumor antigens. The Journal of Clinical Investigation. 2023 https://doi.org/10.1172/JCI166740